Cytoprotective effect of β-lapachone by inducing heme oxygenase-1 expression and AMP-activated protein kinase activation in human endothelial cells

European Review for Medical and Pharmacological Sciences

Volumn 18, Issue 7, 2014, Pages 949-958

  Byun, S J ^a   Son, Y ^a   Pae, H O ^a  

^a Wonkwang University School of Medicine   (South Korea)

Author keywords

AMP activated protein kinase; Endothelial cell; Heme oxygenase 1; Tumor necrosis factor ; Lapachone

Indexed keywords

BETA LAPACHONE; DICOUMAROL; HEME OXYGENASE 1; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTOPORPHYRIN; TUMOR NECROSIS FACTOR; BETA-LAPACHONE; HMOX1 PROTEIN, HUMAN; NAPHTHOQUINONE; NQO1 PROTEIN, HUMAN; PROTECTIVE AGENT; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CELL PROTECTION; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INDUCTION; HUMAN; HUMAN CELL; MTT ASSAY; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING; CELL LINE; CELL SURVIVAL; DRUG EFFECTS; METABOLISM;

AMP-ACTIVATED PROTEIN KINASES; CELL LINE; CELL SURVIVAL; CYTOPROTECTION; ENDOTHELIAL CELLS; HEME OXYGENASE-1; HUMANS; NAD(P)H DEHYDROGENASE (QUINONE); NAPHTHOQUINONES; PROTECTIVE AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84902197731     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. POTENZA MA, GAGLIARDI S, NACCI C., CARRATU MR, MONTAGNANI M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem 2009; 16: 94-112.
2. SHEN GX. Oxidative stress and diabetic cardiovascular disorders: roles of mitochondria and NADPH oxidase. Can J Physiol Pharmacol 2010; 88: 241-248.
3. CHEN X, ANDRESEN BT, HILL M, ZHANG J., BOOTH F, ZHANG C. Role of reactive oxygen species in tumor necrosis factor-alpha-induced endothelial dysfunction. Curr Hypertens Rev 2008; 4: 245-255.
4. XU Q, SI LY Protective effects of AMP-activated protein kinase in the cardiovascular system. J Cell Mol Med 2010; 14: 2604-2613.
5. HAWLEY SA, ROSS FA, CHEVTZOFF C, GREEN K.A., EVANS A., FOGARTY S, TOWLER MC, BROWN L.J., OGUNBAYO OA, EVANS AM, HARDIE DG. Use of cells expressing gamma subunit variants to identify diverse mechanisms of AMPK activation. Cell Metab 2010; 11: 554-565.
6. ZOU MH, WU Y. AMP-activated protein kinase activation as a strategy for protecting vascular endothelial function. Clin Exp Pharmacol Physiol 2008; 35: 535-545. (Pubitemid 351490095)
7. XU Q, SI LY Protective effects of AMP-activated protein kinase in the cardiovascular system. J Cell Mol Med 2010; 14: 2604-2613.
8. LIU XM, PEYTON KJ, SHEBIB A.R., WANG H., KORTHUIS RJ, DURANTE W. Activation of AMPK stimulates heme oxygenase-1 gene expression and human en-dothelial cell survival. Am J Physiol Heart Circ Physiol 2011; 300: H84-H93.
9. LI F.Y., LAM KS, TSE H F, CHEN C, WANG Y., VANHOUTTE PM, XU A. Endothelium-selective activation of AMP-activated protein kinase prevents diabetes mellitus-induced impairment in vascular function and reendothelialization via induction of heme oxygenase-1 in mice. Circulation 2012; 126: 1267-1277.
10. PAE HO, SON Y, KIM N.H., JEONG HJ, CHANG KC, CHUNG HT Role of heme oxygenase in preserving vascular bioactive NO. Nitric Oxide 2010; 23: 251-257.
11. DURANTE W. Protective role of heme oxygenase-1 against inflammation in atherosclerosis. Front Biosci 2011; 16: 2372-2388.
12. DURANTE W. Targeting heme oxygenase-1 in vascular disease. Curr Drug Targets 2010; 11: 1504-1516.
13. PETERSON SJ, FRISHMAN WH, ABRAHAM NG Targeting heme oxygenase: therapeutic implications for diseases of the cardiovascular system. Cardiol Rev 2009; 17: 99-111.
14. DULAK J, LOBODA A, JOZKOWICZ A. Effect of heme oxygenase-1 on vascular function and disease. Curr Opin Lipidol 2008; 19: 505-512.
15. DINKOVA-KOSTOVA A.T., TALALAY P. NAD(P)H: quinone acceptor oxidoreductase 1 (NQO1), a multifunctional antioxidant enzyme and exceptionally versatile cytoprotector. Arch Biochem Biophys 2010; 501: 116-123.
16. ZHU H, LI Y. NAD(P)H: quinone oxidoreductase 1 and its potential protective role in cardiovascular diseases and related conditions. Cardiovasc Toxi-col 2012; 12: 39-45.
17. SIEGEL D, YAN C, ROSS D. NAD(P)H:quinone oxi-doreductase 1 (NQO1) in the sensitivity and resistance to antitumor quinones. Biochem Pharmacol 2012; 83: 1033-1040.
18. PARDEE AB, LI YZ, LI CJ Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002; 2: 227-242.
19. BAE JH, KIM JW, KWEON G.R., PARK MG, JEONG KH, KIM JJ, MOON DU G. Corpus cavernosal smooth muscle relaxation effect of a novel AMPK activator, beta-lapachone. J Sex Med 2011; 8: 2205-2214.
20. KIM S.Y., JEOUNG NH, OH C.J., CHOI YK, LEE HJ, KIM HJ, KIM J.Y., HWANG JH, TADI S, YIM YH, LEE KU, PARK KG, HUH S, MIN KN, JEONG KH, PARK MG, KWAK TH, KWEON GR, INUKAI K, SHONG M, LEE IK. Activation of NAD(P)H: quinone oxidoreductase 1 prevents arterial restenosis by suppressing vascular smooth muscle cell proliferation. Circ Res 2009; 104: 842-850.
21. XIA Z, LIU M, WU Y., SHARMA V, LUO T, OUYANG J., MCNEILL JH. N-acetylcysteine attenuates TNF-alpha-induced human vascular endothelial cell apopto-sis and restores eNOS expression. Eur J Pharmacol 2006; 550: 134-142. (Pubitemid 44572264)
22. OUGH M, LEWIS A, BEY E.A., GAO J., RITCHIE JM, BORNMANN W, BOOTHMAN DA, OBERLEY L.W., CULLEN JJ. Efficacy of beta-lapachone in pancreatic cancer treatment: exploiting the novel, therapeutic target NQO1. Cancer Biol Ther 2005; 4: 95-102. (Pubitemid 41350938)
23. CHOI BT, CHEONG J, CHOI YH beta-Lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-kappaB in human colon cancer HCT-116 cells. Anticancer Drugs 2003; 14: 845-850. (Pubitemid 38339790)
24. LI Y, SUN X, LAMONT J.T., PARDEE AB, LI CJ Selective killing of cancer cells by beta-lapachone: direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA 2003; 100: 2674-2678. (Pubitemid 36297557)
25. PARDEE AB, LI YZ, LI CJ Cancer therapy with beta-lapachone. Curr Cancer Drug Targets 2002; 2: 227-242.
26. JAIN SK, KANNAN K, LIM G., MCVIE R, BOCCHINI JA JR. Hyperketonemia increases tumor necrosis factor-alpha secretion in cultured U937 monocytes and Type 1 diabetic patients and is apparently mediated by oxidative stress and cAMP deficiency. Diabetes 2002; 51: 2287-2293. (Pubitemid 34729037)
27. ZHANG H, PARK Y, WU J., CHEN X P, LEE S, YANG J., DELLSPERGER KC, ZHANG C. Role of TNF-alpha in vascular dysfunction. Clin Sci (Lond) 2009; 116: 219-230.
28. PILLAI VB, SUNDARESAN NR, KIM G, GUPTA M., RAJAMO-HAN SB, PILLAI JB, SAMANT S, RAVINDRA P V, ISBATAN A, GUPTA MP. Exogenous NAD blocks cardiac hyper-trophic response via activation of the SIRT3-LKB1-AMP-activated kinase pathway. J Biol Chem 2010; 285: 3133-3144.
29. FULCO M, CEN Y, ZHAO P., HOFFMAN E P, MCBURNEY MW, SAUVE A.A., SARTORELLI V. Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell 2008; 14: 661-673. (Pubitemid 351622608)
30. YING W. NAD+ and NADH in cellular functions and cell death. Front Biosci 2006; 11: 3129-3148. (Pubitemid 43800402)
31. NAGATA D, HIRATA Y. The role of AMP-activated protein kinase in the cardiovascular system. Hypertens Res 2010; 33: 22-28.
32. SHAH PK, GALIS ZS Matrix metalloproteinase hypothesis of plaque rupture: players keep piling up but questions remain. Circulation 2001; 104: 1878-1880. (Pubitemid 32983226)
33. NEWBY AC. Do metalloproteinases destabilize vulnerable atherosclerotic plaques? Curr Opin Lipidol 2006; 17: 556-561. (Pubitemid 44372687)
34. GENERSCH E, HAYESS K, NEUENFELD Y., HALLER H. Sustained ERK phosphorylation is necessary but not sufficient for MMP-9 regulation in endothelial cells: involvement of Ras-dependent and -independent pathways. J Cell Sci 2000; 113: 4319-4330. (Pubitemid 32004642)
35. JUNCOS J.P., TRACZ MJ, CROATT A.J., GRANDE J P, ACKER-MAN AW, KATUSIC Z.S., NATH KA. Genetic deficiency of heme oxygenase-1 impairs functionality and form of an arteriovenous fistula in the mouse. Kidney Int 2008; 74: 47-51. (Pubitemid 351841888)
36. LI F.Y., LAM KS, TSE H F, CHEN C, WANG Y., VANHOUTTE PM, XU A. Endothelium-selective activation of AMP-activated protein kinase prevents diabetes mellitus-induced impairment in vascular function and reen-dothelialization via induction of heme oxygenase-1 in mice. Circulation 2012; 126: 1267-1277.